About
Pano Therapeutics is developing PAN1195, an oral, once-daily CNS-optimized biguanide aimed at treating Fragile X Syndrome and related syndromic neurodevelopmental disorders through targeted pharmacology.
Explore Pano Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.